Genmab A/S (NASDAQ:GMAB) Reaches New 1-Year Low at $24.94

Genmab A/S (NASDAQ:GMAB) shares reached a new 52-week low during trading on Friday . The company traded as low as $24.94 and last traded at $25.05, with a volume of 53077 shares trading hands. The stock had previously closed at $25.58.

Analyst Upgrades and Downgrades

A number of equities research analysts recently issued reports on the company. BTIG Research raised their price target on Genmab A/S from $46.00 to $47.00 and gave the stock a “buy” rating in a research note on Thursday. Truist Financial boosted their target price on shares of Genmab A/S from $50.00 to $53.00 and gave the company a “buy” rating in a research note on Tuesday, June 4th. HC Wainwright reaffirmed a “buy” rating and issued a $50.00 price target on shares of Genmab A/S in a research note on Thursday. Finally, Morgan Stanley reissued an “underweight” rating on shares of Genmab A/S in a research report on Tuesday, March 26th. Three research analysts have rated the stock with a sell rating, two have issued a hold rating and eight have issued a buy rating to the company. According to data from MarketBeat.com, Genmab A/S has an average rating of “Hold” and an average price target of $49.50.

Genmab A/S Stock Down 1.8 %

The company has a market capitalization of $16.62 billion, a PE ratio of 20.94, a PEG ratio of 0.93 and a beta of 0.99. The business has a 50 day simple moving average of $27.96 and a 200 day simple moving average of $29.11.

Genmab A/S (NASDAQ:GMAB) last released its earnings results on Thursday, May 2nd. The company reported $0.16 EPS for the quarter, hitting analysts’ consensus estimates of $0.16. Genmab A/S had a net margin of 30.74% and a return on equity of 18.90%. The company had revenue of $603.30 million during the quarter, compared to analysts’ expectations of $594.23 million. Equities analysts expect that Genmab A/S will post 1.11 EPS for the current fiscal year.

Hedge Funds Weigh In On Genmab A/S

Several hedge funds have recently made changes to their positions in GMAB. Park Place Capital Corp grew its stake in Genmab A/S by 12.3% during the 4th quarter. Park Place Capital Corp now owns 4,891 shares of the company’s stock valued at $156,000 after purchasing an additional 535 shares during the last quarter. Russell Investments Group Ltd. grew its holdings in Genmab A/S by 137.7% during the first quarter. Russell Investments Group Ltd. now owns 939 shares of the company’s stock worth $28,000 after acquiring an additional 544 shares during the period. Grandfield & Dodd LLC increased its holdings in shares of Genmab A/S by 2.3% during the 4th quarter. Grandfield & Dodd LLC now owns 25,558 shares of the company’s stock valued at $814,000 after purchasing an additional 565 shares in the last quarter. Envestnet Portfolio Solutions Inc. increased its holdings in Genmab A/S by 2.3% in the first quarter. Envestnet Portfolio Solutions Inc. now owns 27,755 shares of the company’s stock valued at $830,000 after buying an additional 633 shares in the last quarter. Finally, Pinnacle Bancorp Inc. boosted its stake in shares of Genmab A/S by 315.8% during the 4th quarter. Pinnacle Bancorp Inc. now owns 840 shares of the company’s stock worth $27,000 after acquiring an additional 638 shares in the last quarter. 7.07% of the stock is owned by institutional investors and hedge funds.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.